Barclays PLC Purchases 53,472 Shares of ChromaDex Co. (NASDAQ:CDXC)

Barclays PLC grew its position in shares of ChromaDex Co. (NASDAQ:CDXC) by 322.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,072 shares of the company’s stock after buying an additional 53,472 shares during the period. Barclays PLC owned approximately 0.09% of ChromaDex worth $256,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CDXC. Bank of New York Mellon Corp increased its position in ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock worth $520,000 after buying an additional 119,915 shares during the period. Rhumbline Advisers bought a new position in shares of ChromaDex in the second quarter worth $124,000. WINTON GROUP Ltd bought a new position in shares of ChromaDex in the second quarter worth $597,000. Dimensional Fund Advisors LP bought a new position in shares of ChromaDex in the second quarter worth $88,000. Finally, Renaissance Technologies LLC increased its position in shares of ChromaDex by 8.4% in the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock worth $1,136,000 after purchasing an additional 32,400 shares during the period. Institutional investors own 15.41% of the company’s stock.

ChromaDex Trading Up 0.5 %

Shares of CDXC stock opened at $5.51 on Monday. The business’s 50-day moving average price is $6.29 and its 200-day moving average price is $4.25. ChromaDex Co. has a 12 month low of $1.36 and a 12 month high of $7.97. The firm has a market capitalization of $420.87 million, a price-to-earnings ratio of 551.55 and a beta of 2.21.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The firm had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same period last year, the firm posted ($0.01) earnings per share. On average, sell-side analysts predict that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CDXC. HC Wainwright raised their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, Roth Mkm lifted their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Insider Activity

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.